Search

Your search keyword '"McInnes, Iain B"' showing total 2,107 results
Start Over Author "McInnes, Iain B"
2,107 results on '"McInnes, Iain B"'

4. Recognition and control of neutrophil extracellular trap formation by MICL

Author

Malamud, Mariano, Whitehead, Lauren, McIntosh, Alasdair, Colella, Fabio, Roelofs, Anke J., Kusakabe, Takato, Dambuza, Ivy M., Phillips-Brookes, Annie, Salazar, Fabián, Perez, Federico, Shoesmith, Romey, Zakrzewski, Przemyslaw, Sey, Emily A., Rodrigues, Cecilia, Morvay, Petruta L., Redelinghuys, Pierre, Bedekovic, Tina, Fernandes, Maria J. G., Almizraq, Ruqayyah, Branch, Donald R., Amulic, Borko, Harvey, Jamie, Stewart, Diane, Yuecel, Raif, Reid, Delyth M., McConnachie, Alex, Pickering, Matthew C., Botto, Marina, Iliev, Iliyan D., McInnes, Iain B., De Bari, Cosimo, Willment, Janet A., and Brown, Gordon D.

Published
2024
Full Text
View/download PDF

14. The nuclear cytokine IL-37a controls lethal cytokine storms primarily via IL-1R8-independent transcriptional upregulation of PPARγ

Author

Wei, Rongfei, Han, Xiao, Li, Mengyuan, Ji, Yuan, Zhang, Lianfeng, Christodoulou, Maria-Ioanna, Hameed Aga, Najwa Jameel, Zhang, Caiyan, Gao, Ran, Liu, Jiangning, Fu, Jinrong, Lu, Guoping, Xiao, Xiaojun, Liu, Xiaoyu, Yang, Ping-Chang, McInnes, Iain B., Sun, Ying, Gao, Peisong, Qin, Chuan, Huang, Shau-Ku, Zhou, Yufeng, and Xu, Damo

Published
2023
Full Text
View/download PDF

16. Immunogenicity of third dose COVID-19 vaccine strategies in patients who are immunocompromised with suboptimal immunity following two doses (OCTAVE-DUO): an open-label, multicentre, randomised, controlled, phase 3 trial

Author

Beesley, Richard, Churchill, Vicky, Insch, Elspeth, Loughton, Holly, MacDonald, Eilean, Lax, Siân, Lowe, Faye, Magwaro, Sophia, Gradwell, Mark, Kinsella, Francesca, Rolfe, Hayley, McIntyre, Stacey, Mortimer, Paige, Al-Taei, Saly, Tadros, Susan, Workman, Sarita, Arnott, Maxine, Brock, James, Melville, Andrew, Najm, Aurelie, Rutherford, Matthew, Sunzini, Flavia, Herman, Lou S, Hobbs, Agnieszka, Ragno, Martina, Wu, Mary Y, Selby, Rachael, Clay, Jennifer, Hutchison, Clare, Lown, Robert, Lwin, May N, Meardon, Naomi, Kelleher, Peter, Lightstone, Liz, Walters, Thomas, Denyer, Jayne, Ibrahim, Rahima, Gleeson, Sarah, Martin, Paul, McAdoo, Stephen, Baker, Helena, Horswill, Sarah, Parungao, Nina, Saich, Stephen, Cullinane, James, Irwin, Sophie, Klenerman, Paul, Marjot, Thomas, Chakraverty, Ronjon, Holroyd, Christopher, Kavi, Janki, Trown, Doreen, Babbage, Gavin, Chackathayil, Julia, Faria, Patricia, Ingham, Karen, Miah, Murad, Miranda, Mauro, O'Reilly, Nicola, Smith, Callie, Driver, Kimberley, Gauntlett, Kaylee, Farthing, Andrew, Rundell, Suzann, Smith, Emily, Tong, Andrew, Woolcock, Kieran, Hanke, Daniel, Laidlaw, Stephen, Malik, Zainab, Nguyen, Dung, Provine, Nicholas, Tipton, Tom, Walker, Victoria, Goodyear, Carl S, Patel, Amit, Barnes, Eleanor, Willicombe, Michelle, Siebert, Stefan, de Silva, Thushan I, Snowden, John A, Lim, Sean H, Bowden, Sarah J, Billingham, Lucinda, Richter, Alex, Carroll, Miles, Carr, Edward J, Beale, Rupert, Rea, Daniel, Parry, Helen, Pirrie, Sarah, Lim, Zixiang, Satsangi, Jack, Dunachie, Susanna J, Cook, Gordon, Miller, Paul, Basu, Neil, Gilmour, Ashley, Hodgkins, Anne-Marie, Evans, Lili, Hughes, Ana, Longet, Stephanie, Meacham, Georgina, Yong, Kwee L, A'Hearne, Matthew J, Koh, Mickey B C, Burns, Siobhan O, Orchard, Kim, Paterson, Caron, McIlroy, Graham, Murray, Sam M, Thomson, Tina, Dimitriadis, Stavros, Goulston, Lyndsey, Miller, Samantha, Keillor, Victoria, Prendecki, Maria, Thomas, David, Kirkham, Amanda, McInnes, Iain B, and Kearns, Pamela

Published
2024
Full Text
View/download PDF

18. SARS-CoV-2-specific immune responses and clinical outcomes after COVID-19 vaccination in patients with immune-suppressive disease

Author

Barnes, Eleanor, Goodyear, Carl S., Willicombe, Michelle, Gaskell, Charlotte, Siebert, Stefan, I de Silva, Thushan, Murray, Sam M., Rea, Daniel, Snowden, John A., Carroll, Miles, Pirrie, Sarah, Bowden, Sarah J., Dunachie, Susanna J., Richter, Alex, Lim, Zixiang, Satsangi, Jack, Cook, Gordon, Pope, Ann, Hughes, Ana, Harrison, Molly, Lim, Sean H., Miller, Paul, Klenerman, Paul, Basu, Neil, Gilmour, Ashley, Irwin, Sophie, Meacham, Georgina, Marjot, Thomas, Dimitriadis, Stavros, Kelleher, Peter, Prendecki, Maria, Clarke, Candice, Mortimer, Paige, McIntyre, Stacey, Selby, Rachael, Meardon, Naomi, Nguyen, Dung, Tipton, Tom, Longet, Stephanie, Laidlaw, Stephen, Orchard, Kim, Ireland, Georgina, Thomas, David, Kearns, Pamela, Kirkham, Amanda, and McInnes, Iain B.

Published
2023
Full Text
View/download PDF

19. Reframing sepsis immunobiology for translation: towards informative subtyping and targeted immunomodulatory therapies

Author

Shankar-Hari, Manu, Calandra, Thierry, Soares, Miguel P, Bauer, Michael, Wiersinga, W Joost, Prescott, Hallie C, Knight, Julian C, Baillie, Kenneth J, Bos, Lieuwe D J, Derde, Lennie P G, Finfer, Simon, Hotchkiss, Richard S, Marshall, John, Openshaw, Peter J M, Seymour, Christopher W, Venet, Fabienne, Vincent, Jean-Louis, Le Tourneau, Christophe, Maitland-van der Zee, Anke H, McInnes, Iain B, and van der Poll, Tom

Published
2024
Full Text
View/download PDF

20. Abatacept in individuals at high risk of rheumatoid arthritis (APIPPRA): a randomised, double-blind, multicentre, parallel, placebo-controlled, phase 2b clinical trial

Author

Norton, Sam, Lempp, Heidi, Opena, Maria, Subesinghe, Sujith, Garrood, Toby, Menon, Bina, Ng, Nora, Douglas, Karen, Koutsianas, Christos, Cooles, Faye, Falahee, Marie, Echavez-Naguicnic, Irene, Bharadwaj, Anurag, Villaruel, Michael, Pande, Ira, Collins, David, Pegler, Suzannah, Raizada, Sabrina, Siebert, Stefan, Fragoulis, George, Guinto, Jesusa, Galloway, James, Rutherford, Andrew, Barnes, Theresa, Jeffrey, Helen, Patel, Yusuf, Batley, Michael, O'Reilly, Brendan, Venkatachalam, Srivinisan, Sheeran, Thomas, Gorman, Claire, Reynolds, Piero, Khan, Asad, Gullick, Nicola, Banerjee, Siwalik, Mankia, Kulveer, Jordan, Deepak, Rowlands, Jane, Starmans-Kool, Mirian, Taylor, James, Nandi, Pradip, Sahbudin, Ilfita, Maybury, Mark, Hider, Samantha, Barcroft, Ann, McNally, Jeremy, Kitchen, Jo, Nisar, Muhammad, Quick, Vanessa, Cope, Andrew P, Jasenecova, Marianna, Vasconcelos, Joana C, Filer, Andrew, Raza, Karim, Qureshi, Sumera, D'Agostino, Maria Antonietta, McInnes, Iain B, Isaacs, John D, Pratt, Arthur G, Fisher, Benjamin A, Buckley, Christopher D, Emery, Paul, Ho, Pauline, Buch, Maya H, Ciurtin, Coziana, van Schaardenburg, Dirkjan, Huizinga, Thomas, Toes, René, Georgiou, Evangelos, Kelly, Joanna, Murphy, Caroline, and Prevost, A Toby

Published
2024
Full Text
View/download PDF

27. The Effect of Guselkumab on Work Productivity in Biologic-Naïve Patients with Active Psoriatic Arthritis Through Week 52 of the Phase 3, Randomized, Placebo-Controlled DISCOVER-2 Trial

Author

Curtis, Jeffrey R., McInnes, Iain B., Rahman, Proton, Gladman, Dafna D., Peterson, Steven, Agarwal, Prasheen, Yang, Feifei, Kollmeier, Alexa P., Hsia, Elizabeth C., Shiff, Natalie J., Zhou, Bei, Han, Chenglong, Shawi, May, Tillett, William, and Mease, Philip J.

Published
2022
Full Text
View/download PDF

30. Bimekizumab in patients with active psoriatic arthritis and previous inadequate response or intolerance to tumour necrosis factor-α inhibitors: a randomised, double-blind, placebo-controlled, phase 3 trial (BE COMPLETE)

Author

Merola, Joseph F, Landewé, Robert, McInnes, Iain B, Mease, Philip J, Ritchlin, Christopher T, Tanaka, Yoshiya, Asahina, Akihiko, Behrens, Frank, Gladman, Dafna D, Gossec, Laure, Gottlieb, Alice B, Thaçi, Diamant, Warren, Richard B, Ink, Barbara, Assudani, Deepak, Bajracharya, Rajan, Shende, Vishvesh, Coarse, Jason, and Coates, Laura C

Published
2023
Full Text
View/download PDF

36. Gait rehabilitation for foot and ankle impairments in early rheumatoid arthritis: a feasibility study of a new gait rehabilitation programme (GREAT Strides)

Author

Hendry, Gordon J., Bearne, Lindsay, Foster, Nadine E., Godfrey, Emma, Hider, Samantha, Jolly, Lisa, Mason, Helen, McConnachie, Alex, McInnes, Iain B., Patience, Aimie, Sackley, Catherine, Sekhon, Mandeep, Stanley, Bethany, van der Leeden, Marike, Williams, Anita E., Woodburn, Jim, and Steultjens, Martijn P. M.

Published
2022
Full Text
View/download PDF

37. Efficacy and Safety of Bimekizumab in Patients With Psoriatic Arthritis With or Without Methotrexate: 52‐Week Results From Two Phase 3 Studies.

Author

McInnes, Iain B., Mease, Philip J., Tanaka, Yoshiya, Gossec, Laure, Husni, M. Elaine, Kristensen, Lars Erik, Warren, Richard B., Ink, Barbara, Bajracharya, Rajan, Coarse, Jason, and Gottlieb, Alice B.

Subjects
ANTI-inflammatory agents, PSORIATIC arthritis, PATIENT safety, RESEARCH funding, DATA analysis, PLACEBOS, BODY mass index, METHOTREXATE, STATISTICAL sampling, BLIND experiment, INVESTIGATIONAL drugs, SEX distribution, QUESTIONNAIRES, ANTIRHEUMATIC agents, RANDOMIZED controlled trials, DESCRIPTIVE statistics, AGE distribution, SEVERITY of illness index, MONOCLONAL antibodies, DRUG efficacy, RESEARCH, STATISTICS, COMPARATIVE studies, CONFIDENCE intervals, SUBCUTANEOUS injections, LIVER function tests, C-reactive protein, INTERLEUKINS, CHEMICAL inhibitors
Abstract

Objective: The objective of this study was to assess 52‐week efficacy and safety of bimekizumab in patients with active psoriatic arthritis (PsA) with or without concomitant methotrexate (+/−MTX) treatment at baseline. Methods: We conducted a post hoc analysis of patients in BE OPTIMAL (NCT03895203; biologic disease‐modifying antirheumatic drug [bDMARD]‐naïve), BE COMPLETE (NCT03896581; prior inadequate response or intolerance to tumor necrosis factor inhibitors [TNFi‐IR]), and the BE VITAL open‐label extension (NCT04009499) study. Patients were randomized to one of the following treatment groups: bimekizumab 160 mg every four weeks, placebo, or a reference drug (adalimumab 40 mg every two weeks; BE OPTIMAL only). From Week 16, placebo‐randomized patients received bimekizumab. Missing data were imputed using non‐responder imputation, multiple imputation, or worst‐category imputation. Results: Through Week 52, similar proportions of bimekizumab‐treated patients achieved American College of Rheumatology 50% (ACR50) response criteria for both +MTX and −MTX (BE OPTIMAL: 54.4% +MTX, 54.7% −MTX; BE COMPLETE: 56.3% +MTX, 48.0% −MTX). Similar proportions of bimekizumab‐treated patients achieved complete skin clearance (Psoriasis Area and Severity Index 100% [PASI100] response) and minimal disease activity in both +MTX and −MTX groups. Similar trends were seen in placebo/bimekizumab‐treated patients. Through Week 52, the proportion of bimekizumab‐treated patients with ≥1 treatment‐emergent adverse event were similar between the +MTX and −MTX groups (BE OPTIMAL 325 of 410 [79.3%] vs 230 of 292 [78.8%], BE COMPLETE 105 of 168 [62.5%] vs 138 of 220 [62.7%]). The safety profile was comparable between subgroups and consistent with the prior safety profile of bimekizumab. Conclusion: Treatment with bimekizumab demonstrated consistent, sustained efficacy to 52 weeks in bDMARD‐naïve and TNFi‐IR patients with PsA and was well tolerated, irrespective of concomitant MTX. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

38. Association of the clinical components in the distal interphalangeal joint synovio-entheseal complex and subsequent response to ixekizumab or adalimumab in psoriatic arthritis.

Author

McGonagle, Dennis, Kavanaugh, Arthur, McInnes, Iain B, Kristensen, Lars Erik, Merola, Joseph F, Strober, Bruce, Bolce, Rebecca, Lisse, Jeffrey, Pustizzi, Jennifer, Sapin, Christophe, and Ritchlin, Christopher

Subjects
THERAPEUTIC use of monoclonal antibodies, FINGER joint, PSORIATIC arthritis, DATA analysis, RESEARCH funding, TREATMENT effectiveness, CHI-squared test, DESCRIPTIVE statistics, LONGITUDINAL method, ADALIMUMAB, STATISTICS, INTERLEUKINS, TUMOR necrosis factors, NAIL diseases, CHEMICAL inhibitors
Abstract

Objectives To assess the frequency of simultaneous distal interphalangeal (DIP) joint disease and adjacent nail psoriasis (finger unit) among patients with psoriatic arthritis (PsA) and compare the efficacy of the IL-17A antagonist ixekizumab (IXE) and the TNF-α inhibitor adalimumab (ADA). Methods This post hoc analysis evaluated the simultaneous occurrence of DIP joint involvement (tenderness and/or swelling) and adjacent nail psoriasis among patients with PsA from the SPIRIT-H2H (NCT03151551) trial comparing IXE to ADA. Among patients with simultaneous DIP joint involvement and adjacent nail psoriasis in ≥1 digit at baseline, treatment effects were assessed through week 52 for each affected finger unit; 'finger unit' defines the connected DIP joint and adjacent nail of an individual digit. Results A total of 354 patients had simultaneous DIP joint involvement and adjacent nail psoriasis in ≥1 finger unit at baseline. Among them, 1309 (IXE: 639; ADA: 670) finger units had baseline DIP joint tenderness and/or swelling and adjacent nail psoriasis. Proportions of affected finger units achieving complete resolution were significantly higher with IXE vs ADA as early as week 12 (38.8% vs 28.4%, P  < 0.0001) and at all post-baseline assessments through week 52 (64.9% vs 57.5%, P  = 0.0055). Conclusion In this study cohort, patients with DIP joint involvement almost always had adjacent nail psoriasis. Greater resolution of DIP joint tenderness, swelling and adjacent nail psoriasis was achieved at all time points over 52 weeks through targeting IL-17A with IXE than TNF-α with ADA, which is noteworthy given prior comparable musculoskeletal outcomes for both drug classes. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

41. Treating axial spondyloarthritis and peripheral spondyloarthritis, especially psoriatic arthritis, to target: 2017 update of recommendations by an international task force

Author

Smolen, Josef S, Schöls, Monika, Braun, Jürgen, Dougados, Maxime, FitzGerald, Oliver, Gladman, Dafna D, Kavanaugh, Arthur, Landewé, Robert, Mease, Philip, Sieper, Joachim, Stamm, Tanja, Wit, Maarten de, Aletaha, Daniel, Baraliakos, Xenofon, Betteridge, Neil, Bosch, Filip van den, Coates, Laura C, Emery, Paul, Gensler, Lianne S, Gossec, Laure, Helliwell, Philip, Jongkees, Merryn, Kvien, Tore K, Inman, Robert D, McInnes, Iain B, Maccarone, Mara, Machado, Pedro M, Molto, Anna, Ogdie, Alexis, Poddubnyy, Denis, Ritchlin, Christopher, Rudwaleit, Martin, Tanew, Adrian, Thio, Bing, Veale, Douglas, Vlam, Kurt de, and van der Heijde, Désirée

Subjects
Biomedical and Clinical Sciences, Clinical Sciences, Arthritis, Autoimmune Disease, Clinical Research, Rare Diseases, Inflammatory and immune system, Advisory Committees, Arthritis, Psoriatic, Axis, Cervical Vertebra, Consensus, Decision Making, Humans, Severity of Illness Index, Spondylitis, Ankylosing, Ankylosing Spondylitis, Outcomes Research, Psoriatic Arthritis, Spondyloarthritis, Treatment, Immunology, Public Health and Health Services, Arthritis & Rheumatology, Clinical sciences
Abstract

Therapeutic targets have been defined for axial and peripheral spondyloarthritis (SpA) in 2012, but the evidence for these recommendations was only of indirect nature. These recommendations were re-evaluated in light of new insights. Based on the results of a systematic literature review and expert opinion, a task force of rheumatologists, dermatologists, patients and a health professional developed an update of the 2012 recommendations. These underwent intensive discussions, on site voting and subsequent anonymous electronic voting on levels of agreement with each item. A set of 5 overarching principles and 11 recommendations were developed and voted on. Some items were present in the previous recommendations, while others were significantly changed or newly formulated. The 2017 task force arrived at a single set of recommendations for axial and peripheral SpA, including psoriatic arthritis (PsA). The most exhaustive discussions related to whether PsA should be assessed using unidimensional composite scores for its different domains or multidimensional scores that comprise multiple domains. This question was not resolved and constitutes an important research agenda. There was broad agreement, now better supported by data than in 2012, that remission/inactive disease and, alternatively, low/minimal disease activity are the principal targets for the treatment of PsA. As instruments to assess the patients on the path to the target, the Ankylosing Spondylitis Disease Activity Score (ASDAS) for axial SpA and the Disease Activity index for PSoriatic Arthritis (DAPSA) and Minimal Disease Activity (MDA) for PsA were recommended, although not supported by all. Shared decision-making between the clinician and the patient was seen as pivotal to the process. The task force defined the treatment target for SpA as remission or low disease activity and developed a large research agenda to further advance the field.

Published
2018

42. Immunogenicity of third dose COVID-19 vaccine strategies in patients who are immunocompromised with suboptimal immunity following two doses (OCTAVE-DUO): an open-label, multicentre, randomised, controlled, phase 3 trial

Author

Goodyear, Carl S, primary, Patel, Amit, additional, Barnes, Eleanor, additional, Willicombe, Michelle, additional, Siebert, Stefan, additional, de Silva, Thushan I, additional, Snowden, John A, additional, Lim, Sean H, additional, Bowden, Sarah J, additional, Billingham, Lucinda, additional, Richter, Alex, additional, Carroll, Miles, additional, Carr, Edward J, additional, Beale, Rupert, additional, Rea, Daniel, additional, Parry, Helen, additional, Pirrie, Sarah, additional, Lim, Zixiang, additional, Satsangi, Jack, additional, Dunachie, Susanna J, additional, Cook, Gordon, additional, Miller, Paul, additional, Basu, Neil, additional, Gilmour, Ashley, additional, Hodgkins, Anne-Marie, additional, Evans, Lili, additional, Hughes, Ana, additional, Longet, Stephanie, additional, Meacham, Georgina, additional, Yong, Kwee L, additional, A'Hearne, Matthew J, additional, Koh, Mickey B C, additional, Burns, Siobhan O, additional, Orchard, Kim, additional, Paterson, Caron, additional, McIlroy, Graham, additional, Murray, Sam M, additional, Thomson, Tina, additional, Dimitriadis, Stavros, additional, Goulston, Lyndsey, additional, Miller, Samantha, additional, Keillor, Victoria, additional, Prendecki, Maria, additional, Thomas, David, additional, Kirkham, Amanda, additional, McInnes, Iain B, additional, Kearns, Pamela, additional, Beesley, Richard, additional, Churchill, Vicky, additional, Insch, Elspeth, additional, Loughton, Holly, additional, MacDonald, Eilean, additional, Lax, Siân, additional, Lowe, Faye, additional, Magwaro, Sophia, additional, Gradwell, Mark, additional, Kinsella, Francesca, additional, Rolfe, Hayley, additional, McIntyre, Stacey, additional, Mortimer, Paige, additional, Al-Taei, Saly, additional, Tadros, Susan, additional, Workman, Sarita, additional, Arnott, Maxine, additional, Brock, James, additional, Melville, Andrew, additional, Najm, Aurelie, additional, Rutherford, Matthew, additional, Sunzini, Flavia, additional, Herman, Lou S, additional, Hobbs, Agnieszka, additional, Ragno, Martina, additional, Wu, Mary Y, additional, Selby, Rachael, additional, Clay, Jennifer, additional, Hutchison, Clare, additional, Lown, Robert, additional, Lwin, May N, additional, Meardon, Naomi, additional, Kelleher, Peter, additional, Lightstone, Liz, additional, Walters, Thomas, additional, Denyer, Jayne, additional, Ibrahim, Rahima, additional, Gleeson, Sarah, additional, Martin, Paul, additional, McAdoo, Stephen, additional, Baker, Helena, additional, Horswill, Sarah, additional, Parungao, Nina, additional, Saich, Stephen, additional, Cullinane, James, additional, Irwin, Sophie, additional, Klenerman, Paul, additional, Marjot, Thomas, additional, Chakraverty, Ronjon, additional, Holroyd, Christopher, additional, Kavi, Janki, additional, Trown, Doreen, additional, Babbage, Gavin, additional, Chackathayil, Julia, additional, Faria, Patricia, additional, Ingham, Karen, additional, Miah, Murad, additional, Miranda, Mauro, additional, O'Reilly, Nicola, additional, Smith, Callie, additional, Driver, Kimberley, additional, Gauntlett, Kaylee, additional, Farthing, Andrew, additional, Rundell, Suzann, additional, Smith, Emily, additional, Tong, Andrew, additional, Woolcock, Kieran, additional, Hanke, Daniel, additional, Laidlaw, Stephen, additional, Malik, Zainab, additional, Nguyen, Dung, additional, Provine, Nicholas, additional, Tipton, Tom, additional, and Walker, Victoria, additional

Published
2024
Full Text
View/download PDF

43. IL-23 past, present, and future: a roadmap to advancing IL-23 science and therapy

Author

Krueger, James G., primary, Eyerich, Kilian, additional, Kuchroo, Vijay K., additional, Ritchlin, Christopher T., additional, Abreu, Maria T., additional, Elloso, M. Merle, additional, Fourie, Anne, additional, Fakharzadeh, Steven, additional, Sherlock, Jonathan P., additional, Yang, Ya-Wen, additional, Cua, Daniel J., additional, and McInnes, Iain B., additional

Published
2024
Full Text
View/download PDF

44. Efficacy and safety of pharmacological treatment of psoriatic arthritis: a systematic literature research informing the 2023 update of the EULAR recommendations for the management of psoriatic arthritis

Author

Kerschbaumer, Andreas, primary, Smolen, Josef S, additional, Ferreira, Ricardo J O, additional, Bertheussen, Heidi, additional, Baraliakos, Xenofon, additional, Aletaha, Daniel, additional, McGonagle, Dennis G, additional, van der Heijde, Désirée, additional, McInnes, Iain B, additional, Esbensen, Bente Appel, additional, Winthrop, Kevin L, additional, Boehncke, Wolf-Henning, additional, Schoones, Jan W, additional, and Gossec, Laure, additional

Published
2024
Full Text
View/download PDF

45. EULAR recommendations for the management of psoriatic arthritis with pharmacological therapies: 2023 update

Author

Gossec, Laure, primary, Kerschbaumer, Andreas, additional, Ferreira, Ricardo J O, additional, Aletaha, Daniel, additional, Baraliakos, Xenofon, additional, Bertheussen, Heidi, additional, Boehncke, Wolf-Henning, additional, Esbensen, Bente Appel, additional, McInnes, Iain B, additional, McGonagle, Dennis, additional, Winthrop, Kevin L, additional, Balanescu, Andra, additional, Balint, Peter V, additional, Burmester, Gerd R, additional, Cañete, Juan D, additional, Claudepierre, Pascal, additional, Eder, Lihi, additional, Hetland, Merete Lund, additional, Iagnocco, Annamaria, additional, Kristensen, Lars Erik, additional, Lories, Rik, additional, Queiro, Rubén, additional, Mauro, Daniele, additional, Marzo-Ortega, Helena, additional, Mease, Philip J, additional, Nash, Peter, additional, Wagenaar, Wendy, additional, Savage, Laura, additional, Schett, Georg, additional, Shoop-Worrall, Stephanie J W, additional, Tanaka, Yoshiya, additional, Van den Bosch, Filip E, additional, van der Helm-van Mil, Annette, additional, Zabotti, Alen, additional, van der Heijde, Désirée, additional, and Smolen, Josef S, additional

Published
2024
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results